CLINICAL_TRIALS
trial_result
· 2012-07-23
Clinical Trial Update: Study Effect of VIA-2291 on Vascular Inflammation [Phase 2]
Summary
Phase 2 trial evaluating VIA-2291 for reducing vascular inflammation in coronary artery disease was completed, with results posted in July 2012.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Tallikut Pharmaceuticals, Inc. | Conditions: Coronary Artery Disease | Phase 2 | Status: COMPLETED | Results posted: 2012-07-23